A Trial to Evaluate the Efficacy and Safety of Tafasitamab With Bendamustine (BEN) Versus Rituximab (RTX) With BEN in Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) (B-MIND)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT02763319 |
|
Recruitment Status :
Active, not recruiting
First Posted : May 5, 2016
Last Update Posted : August 2, 2022
|
Sponsor:
MorphoSys AG
Collaborator:
ICON Clinical Research
Information provided by (Responsible Party):
MorphoSys AG
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Active, not recruiting |
|---|---|
| Estimated Primary Completion Date : | June 2024 |
| Estimated Study Completion Date : | June 2024 |